Loramyc®/Oravig®

Onxeo Divests Two Non-Core Products in Oral Pathologies to Vectans Pharma

Transaction confirms Onxeo’s strategic focus on innovative orphan oncology drugs Paris (France), July 31, 2017 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the sale of two historical products…read more →

BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig®

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, updates on Loramyc®/Oravig® development programs by its Asian partners and on its US partnership. In the United States, after one year of marketing by American partner Vestiq Pharmaceutical, the sales performance of Oravig® was not meeting the expectations. Consequently, BioAlliance…read more →

BioAlliance Pharma’s partner, Sosei, announces a partnership with FUJIFILM Pharma for commercialization rights for Loramyc® in Japan

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced that its Japanese partner, Sosei Co. Ltd, has entered into a distribution agreement with FUJIFILM Pharma Co., Ltd, for commercialization rights in Japan for Loramyc® (miconazole Lauriad®) mucoadhesive tablet. In May 2011, BioAlliance Pharma signed a licensing agreement with Sosei to…read more →

Key milestones and consolidated accounts First semester 2013

Grant of the Marketing Authorization for Sitavig® in the US Strong achievements in clinical trials with Livatag® (phase III) and Validive® (phase II) Significant reinforcement of cash reserves thanks to the capital increase of July 2013 BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, today…read more →

BioAlliance Pharma’s Sitavig® receives Market Authorization in the US for the treatment of Herpes Labialis

Second BioAlliance Pharma drug registered in the US An effective and innovative medicine for the treatment of a frequent infection, recurrent Herpes labialis in adults BioAlliance Pharma SA (Euronext Paris – BIO), today announced the receipt of marketing authorization from the U.S. Food and Drug Administration (FDA) for Sitavig® in the treatment of recurring Herpes labialis, marking the successful conclusion…read more →

Bioalliance Pharma updates on major achievements of 2012 and publishes its 2012 consolidated financial statements and income for Q1 2013

Successful key milestones reached on all orphan oncology clinical programs First registration of Sitavig granted in European countries Oravig licensing agreement signed for US Income growth and operating costs under control. Paris, April 15, 2013 – BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company dedicated to the development of orphan oncology products and to supportive care products today…read more →

BioAlliance Pharma pursues the development plan of its Loramyc® in Japan through its partner Sosei – Initiation of the pivotal registration phase III trial

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the initiation of Loramyc®/Oravig® Phase III clinical trial for the treatment of oropharyngeal candidiasis by its Japanese partner Sosei. This is the final step before registration of the drug by Japanese authorities. In May 2011, BioAlliance…read more →

BioAlliance Pharma signs a collaborative agreement with one of the worldwide leaders in vaccines for a vaccine application of its patented Lauriad® mucoadhesive technology

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces a collaboration agreement with one of the world leading vaccine companies to develop a vaccine application of its Lauriad® mucoadhesive technology. The terms of this agreement are not disclosed at this time. This research program aims…read more →

BioAlliance Pharma announces the launch of Oravig® in the United States by its new partner, Vestiq Pharmaceuticals

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the launch of Oravig® (known as Loramyc® in Europe) in the United States by its commercial partner, Vestiq Pharmaceuticals. Just three months after the signature of the license agreement between the two Companies, commercial teams have…read more →

BioAlliance Pharma receives a guarantee from Coface to finance its export activities Paris,

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the signature of an assurance prospection agreement with Coface granting a guarantee to finance its export activities. Under this agreement, Coface will cover the expenses incurred by BioAlliance Pharma in the prospect of export markets for…read more →